Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Semaglutide

GLP-1 receptor agonist31 amino acidsBrand: Ozempic, Wegovy, Rybelsus

AFDA Approved
95
Excellent Credibility
3 cited studies | Evidence level A

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Mechanism of Action

Mimics endogenous GLP-1, binding to GLP-1 receptors in the pancreas, gut, and brain. Enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic signaling.

Benefits

  • Mean 15% body weight loss in obesity trials (STEP 1)[1]
  • Significant HbA1c reduction in type 2 diabetes[2]
  • Reduced major cardiovascular events (SELECT trial)[3]
  • Available in oral formulation (Rybelsus)[2]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Semaglutide - Dosing in Published Research

Reported routes: Subcutaneous injection, Oral
Ozempic: titrated from 0.25 mg to 0.5-1 mg SC weekly. Wegovy: titrated to 2.4 mg SC weekly. Rybelsus: 3-14 mg oral daily.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting (especially during titration)[1]
  • Diarrhea or constipation[1]
  • Pancreatitis risk (rare)[1]
  • Gallbladder disorders[1]
  • Potential thyroid C-cell tumor risk (animal studies)[1]

Discuss Semaglutide with a doctor

Semaglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.

Start Visit at Henry Meds

Get evaluated by a board-certified clinician via Henry Meds. same-week telehealth visits.

FDA approvedBoard-certified doctorsPrescription if appropriate

PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.

Approved Treatment Routing

Semaglutide in PeptideScholar's approved-treatment dataset

Semaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Ozempic, Wegovy, Rybelsus.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.

Semaglutide Next Steps

US-first money path
Treatment Hub
Semaglutide Treatment Guide

Approved product paths, real cost friction, provider routing, and tracker next steps — all in one source-backed hub.

Open treatment hub →

Research & Evidence

Compare Semaglutide With

References

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 2021. "Semaglutide 2.4 mg produced 14.9% mean body weight loss vs 2.4% with placebo over 68 weeks in 1,961 adults" [PMID: 33567185]
  2. 2.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. N Engl J Med, 2016. "Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in type 2 diabetes patients" [PMID: 27633186]
  3. 3.Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).. N Engl J Med, 2023. "Semaglutide reduced major adverse cardiovascular events by 20% vs placebo in adults with obesity and established CVD but no diabetes" [PMID: 37952131]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

GLP-1 Support Essentials

Products to help manage side effects and optimize outcomes during treatment.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Progress Tracking Tools

Monitor weight, body composition, and nutrition to maximize results.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Semaglutide FAQ